Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer.

ABSTRACT:

Background

Lutetium-177 [¹⁷⁷Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer. The presence of PSMA-negative/FDG-positive metastases can preclude patients from being eligible for this treatment. Biology-guided radiotherapy (BgRT) is a treatment modality that utilises tumour PET emissions to guide external beam radiotherapy. The feasibility of combining BgRT and Lutetium-177 [¹⁷⁷Lu]-PSMA-617 for patients with PSMA-negative/FDG-positive metastatic prostate cancer was explored.

Materials and methods

All patients excluded from the LuPSMA clinical trial (ID: ANZCTR12615000912583) due to PSMA/FDG discordance were retrospectively reviewed. A hypothetical workflow

SUBMITTER: Gaudreault M 

PROVIDER: S-EPMC10040757 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature